Tech Transfer Roundup: Universities And Biotechs Continue To Look For Ways To Combat COVID-19
Executive Summary
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
You may also be interested in...
Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
AlloVir Gains PRIME Status For Anti-Virus T-Cell Therapy
Joining the ElevateBio stable last May, the company has now gained priority status in the US and Europe for its novel therapy for viral infections in stem cell transplant patients.
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.